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Abstract. Three mutations of the membrane-binding 
re#on of the Semliki Forest virus (SFV) 1062 polypep- 
tide (the precursor for virion E3 and E2) have been 
made by oligonucleotide-directed mutagenesis of a 
cDNA clone encoding the SFV structural proteins. 
One of the mutations (A2) substitutes a Glu for an 
Ala in the middle of the hydrophobic stretch which 
spans the bilayer. Al and A3 alter the two basic 
charged amino acids in the cytoplasmic domain next 
to the hydrophobic region. The wild-type charge clus- 
ter of Arg-Ser-Lys (+2) has been changed to Gly-Ser- 
Met (0;A3) or to Gly-Ser-Glu (-I;A 1). The mutant 
p62 proteins have been analyzed both in the presence 
and the absence of E 1, the other half of the heterodi- 
mer spike complex of SFV. The mutant proteins ex- 
pressed in COS-7 cells are glycosylated and are of the 
expected sizes. When co-expressed with E 1, all three 
mutants are cleaved to yield the E2 protein and trans- 
ported to the surface of COS-7 cells. When expressed 
in the absence of E l, the mutant p62 proteins remain 
uncleaved but still reach the cell surface. Once at the 
cell surface, all three mutants, when co-expressed with 
El, can promote low pH-triggered cell-cell fusion. 
These results show that the three mutant p62/E2 pro- 
teins are still membrane associated in a functionally 
unaltered way. 
T  RANSMEMBRANE proteins that span the lipid bilayer 
once can be divided into three protein domains: lu- 
menal (or external), transmembrane (or hydrophobic), 
and cytoplasmic. Some of these proteins have been shown to 
be oriented in the membrane with their COOH-terminus in 
the cytoplasm (group I membrane proteins; see reference 16) 
while others have the opposite orientation (group II). We are 
attempting to define the features of group I transmembrane 
proteins that lead to the establishment and maintenance of 
their three-domain structure. 
A large number of biochemical and structural studies (e.g., 
8, 13, 23, 42, 47, 49, 51) on group I proteins have demonstra- 
ted that the transmembrane protein domain consists of  a long 
stretch (20-30) of hydrophobic and neutral amino acid resi- 
dues.  In  addition,  sequence comparisons  between group  I 
proteins have revealed that the hydrophobic peptide is always 
followed by one  or  more  positively charged residues (the 
"charge cluster") immediately preceding the cytoplasmic do- 
main.  These basic residues have  also been  implicated  in 
membrane  binding,  e.g., by  interacting  with  negatively 
charged phospholipid headgroups on the cytoplasmic mem- 
brane surface (47, 51). The observation that the transmem- 
brane peptide and the charge cluster of group I proteins are 
generally encoded by one single exon (e.g. 20,  34) supports 
the notion that the two consensus features are functionally 
related. Our working hypothesis is that the region containing 
the hydrophobic transmembrane domain and the charge clus- 
ter  of the  cytoplasmic domain  make  up  the  membrane- 
binding region of  group I proteins. 
It has been  postulated that the generation of the three- 
domain structure of  group I proteins occurs co-translationally. 
Group I proteins have been shown to be inserted across the 
endoplasmic reticulum membrane starting from their NH2- 
termini using the same mechanism as secretory proteins (see, 
e.g., 25, 26, and 33). However, in contrast to secretory pro- 
teins, where chain transfer is completed, translocation of a 
membrane protein chain is thought to be arrested at the level 
of its hydrophobic segment by a "stop transfer signal," thus 
resulting in a transmembrane protein (4; for review see ref- 
erence 47). A most likely candidate for this "stop transfer 
signal" could be the  membrane-binding region of group  I 
proteins. Such a role for this region is supported by a great 
deal of  evidence derived both from natural variants of  certain 
proteins and more recently from studies with mutations en- 
gineered in vitro. The evidence may be arranged into several 
categories. Firstly, loss of both  hydrophobic  domain  and 
cytoplasmic tail, as would be predicted, leads to secretion 
from the cell (IgG, IgM, IgA, and IgD [e.g., 2, 44], Herpes 
envelope protein [24], and H-2 related pH 16 [30] are natural 
variants; influenza hemagglutinin [17], and  Vesicular Sto- 
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deliberate engineering). Alternatively, the truncated proteins 
are still cell associated but no longer transmembrane proteins 
(one mutant of the low density lipoprotein receptor provides 
a  natural example [32];  phage F1  gene III protein [5]  and 
Rous  Sarcoma virus  envelope protein  [53]  are  engineered 
examples). These data do not exclude the possibility that the 
cytoplasmic tail could be involved in anchoring. However, 
there are examples of proteins in  which  the  normal  cyto- 
plasmic tail alone has been partially or completely (with the 
exception of the  charge  cluster)  removed,  and  membrane 
association is apparently not affected. H-2 antigens (56), VSV- 
G  (46),  influenza hemagglutinin (12),  Semliki Forest virus 
(SFV) E2 ( ! 5), and Rous Sarcoma virus envelope protein (53) 
have all been investigated in this respect. To demonstrate that 
the functioning of the hydrophobic domain is also independ- 
ent of the lumenal domain, the lumenal domains of several 
group I proteins have been exchanged generating fusion pro- 
teins that are still membrane associated (FI gene III protein/ 
gene VIII  protein  [5],  SFV-E2/VSV-G  [43],  SFV-E2/Fowl 
Plague  virus-hemagglutinin  [43],  growth  hormone/VSV-G 
[19], and influenza hemagglutinin/VSV-G [38]). Finally, and 
most elegantly, Yost et al. (54) placed the membrane-binding 
polypeptide region of an IgM heavy chain between the bac- 
terial ¢~-lactamase (NH2-terminal) and chimpanzee a-globin 
(COOH-terminal). This chimera had the topology predicted 
by the stop transfer postulate. 
We decided to study the features of the membrane-binding 
region of a  group I  polypeptide that  are important for its 
function using the extremely powerful approach of in vitro 
mutagenesis followed by in vivo expression. The model pro- 
tein we are using is the well-characterized group I  protein 
p62/E2 of SFV (14,  48) (see  also Figs.  1 and 4).  The p62 
protein is a  486-amino acid  residues-long transmembrane 
spike glycoprotein which is synthesized in the rough endo- 
plasmic reticulum and then transported as a  complex with 
the other SFV spike glycoprotein E1  to the cell surface.  At 
the plasma membrane, the p62 protein is cleaved after residue 
66 to form E3 and E2. The p62/E2 protein has a 3 l-residue 
COOH-terminal cytoplasmic tail with a "typical" charge clus- 
ter (Arg-Ser-Lys) flanking the transmembrane domain. Using 
oligonucleotide-directed  mutagenesis,  three  mutants  have 
been produced in the membrane-binding region: A 1, changing 
the positive charge cluster from Arg-Ser-Lys (+2) to Gly-Ser- 
Glu (-1); A2, substitution of the negatively charged Glu for 
an Ala in the middle of the uncharged hydrophobic spanning 
region; A3, changing the charge cluster from wild type (+2) 
to Gly-Ser-Met (0). 
The phenotypes of the p62/E2 mutants will depend on the 
function of the  altered regions in  translocation arrest and 
membrane binding. It was originally proposed (4) that a "stop 
transfer" signal was recognized by some element of the trans- 
location machinery, causing the disassembly of a  proteina- 
ceous tunnel in the membrane through which secretory and 
membrane proteins are translocated, thereby trapping a mem- 
brane protein in  the bilayer. According to this model, the 
mutants  might  no  longer have  functional  signals  and  the 
Abbreviations used in this'paper: DME, Dulbecco's modified Eagle's medium: 
dsDNA,  double-stranded  DNA:  SFV,  Semliki Forest  virus: ssDNA,  single- 
stranded DNA; VSV-G, Vesicular Stomatitis virus glycoprotein. 
tunnel might then remain in place. The proteins would then 
complete translocation becoming lumenal proteins, either cell 
associated or secreted. On the other hand, if the membrane- 
binding region interacts either directly with the lipid bilayer, 
or is recognized in a degenerate fashion by the translocation 
machinery, then the mutations may have more subtle effects 
on membrane binding and/or topology. The mutant pheno- 
types would then reflect the relative roles of the two features 
of this region in establishment and maintenance of topology. 
In  this  paper,  we  show  that  all  three  mutants  are  still 
membrane associated in a functionally unaltered fashion since 
they are all capable of reaching the cell surface where they 
can promote normal low pH-triggered cell-cell fusion. In the 
accompanying paper we assay the topology and membrane- 
binding capacity of the SFV-A mutants directly. 
Materials and Methods 
General DNA Manipulations 
Except where stated, all enzymes were from Boehringer Mannheim Biochemi- 
cals, Indianapolis, IN or New England Biolabs, Beverly, MA. General molecular 
biological techniques were  performed  as  described  (35).  Transformation  of 
Escherichia coli (except where otherwise stated, strain 71/18  [40]) was per- 
formed as in Hanahan (21). Preparation of DNA was as described (27). 
Vectors 
To construct pSFd, the origin of replication of the phage FI was isolated from 
pD4 (l l) as an EcoRl  fragment, and the ends were filled in and then ligated 
into pS-S-SFV  at the PvulI site. One of the two EcoRl sites was recreated (see 
Fig. 2 a). 
Wild-type pS-S-SFV  has been described elsewhere (27).  pLI-SFV was ob- 
tained by isolating the Hind Ill-Hind Ill fragment which codes for the SFV 
structural proteins from pS-S-SFV,  filling in the ends, adding Barn HI linkers, 
and cloning it into the unique BamHl site of pAl I-SVL2 (18). 
pLI-SFV-d9 was derived from pSV2-SFV-d9 (one of the series of the SFV 
deletion mutations described by Garoff et al.  [15]).  The deletion mutant d9 
encodes capsid and p62  but not El.  In d9, the truncated 6K  is followed by 
eight aberrant amino acids introduced by the stop translation linker (Garoff, 
H., unpublished data), pLI-SFV-d9 was produced by a three-fragment ligation. 
Fragments were prepared as follows. (a) pSV2-SFV-d9 was linearized with Hind 
Ill, the ends filled in and BamHI linkers added. This was then cleaved with 
Clal and the Clal-BamHI fragment containing the SFV  coding region  was 
isolated. (b)  pkTH601  (41)  was cut  with  BamHI  and  Cla  I  and  the  small 
fragment containing the translation stop linker was isolated. (c) pAII-SVL2 
was cut with BamHl and treated with phosphatase. All three isolated fragments 
were then ligated together, and colonies resulting from transformation screened 
for pLI-SFV-d9 by restriction analysis. 
Mutagenesis 
Oligonucleotides were purchased from  Dr.  Kaplan, City of Hope,  Research 
Institute, Duarte, CA. 
Mutagenesis of SFV-AI and A2.  Following the procedures of Dente et al. 
(10),  single-stranded DNA (ssDNA) was prepared from pSFd. The conversion 
of this  material to  double-stranded (ds)  pSFd  incorporating the  mutagenic 
oligonucleotide  in vitro was as described in Zoller and Smith (55) using Klenow 
(Bethesda Research Laboratories. Gaithersburg, MD) and T4-DNA ligasc (kind 
gift of F.  Winkler, Hoffman-LaRoche, Basel, Switzerland). The heteroduplex 
was cut with SstII, the small fragment isolated and ligated into the large fragment 
isolated from Sstll-digested, phosphatase-treated pS-S-SFV.  This ligation was 
used to transform E. coli and resultant colonies were screened for mutants by 
hybridization to the mutagenic oligonucleotide  as described in Canner et al. (7), 
The putative mutants of pS-S-SFV were digested with Pvull and Scal, and the 
ends were filled in. The small fragment isolated and ligated into M 13 mp8 (39, 
40) that had been cut with Sinai and phosphatased (see Fig. 2 b).  M I3 mp8- 
SFV was then used for confirmatory sequencing between the Sstll sites using 
the dideoxy chain-terminating method. The mutant pS-S-SFVs were then used 
for expression or used  for subcloning the  mutants into pL1-SFV  and  pLI- 
SFV-d9. 
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S-SFV as described above. MI3 mpl8 was digested with EcoRl  and Hind Ill. 
The large fragment was isolated and 2 pmol incubated in 16 #1 of buffer A (25 
mM Tris, pH 7.5, 60 mM NaCI, 12.5 mM MgCI2, 2 mM dithiothreitol) at 95"C 
for  10 min.  0.5 pmol (l  #1) of ssMl3 mpS-SFV was added and the material 
transferred to 65"C for l h, followed by addition  of 30 pmol (3 ul) of kinased 
oligonucleotide. The mixture was then slowly cooled to room temperature.  18 
ul of buffer C (buffer A +  1 mM of each dNTP +  1 mM ATP)followed  by  1 
U DNA ligase and 2.5 U DNA polymerase  1 (large fragment) were added, and 
incubated  for 3 h at  16"C. Aliquots  were used to transform  ES871 (6), and 
hybridization  screening  was  carried  out  as  for  SFV-A1/A2.  Confirmatory 
sequencing between Sst-Ii sites was carried out by the dideoxy method in m13 
mplS-S-SFV  and  the  SstII-Sstll fragment  was subeloned  into  the  various 
expression vectors. 
DEAE-Dextran-mediated  Transfection of COS- 
7 Cells 
Subconfluent  monolayers of COS-7 cells (-2 x  10  ~ cells) on 5-cm dishes were 
transfected as follows. Plasmid DNA was diluted in RPMI  1640 (Gibeo, Grand 
Island, NY) to 4 #g/ml and mixed with an equal volume of DEAE--dextran 
(Pharmacia  Fine  Chemicals,  Piscataway, NJ;  molecular  weight, 5 x  105) in 
RPMI  1640 at a concentration  of 2 mg/ml. Cells were washed twice with RPMI 
and  then  incubated  with  the  DNA  mix  (1  ml/dish).  After  1 h  at  room 
temperature,  5 ml of Dulbecco's modified Eagle's medium (DME) with  10% 
fetal calf serum and 10% dimethyl sulfoxide were added. 3 min later, the cells 
were washed twice with DME plus 10% fetal calf serum supplemented with 40 
uM chloroquine (Sigma Chemical Co., St. Louis, MO) and left in this solution 
for 6 h at 37"C. The cells were then washed and incubated  for 30 or 40 h at 
37"C in 5 ml DME plus 10% fetal calf serum before labeling, fixation, or lysis. 
Microinjection, Immunofluorescence,  Western 
Blotting, and Gel Electrophoresis 
Microinjection and indirect immunofluorescence  were performed as described 
(50). Western blotting was performed as described in Kondor-Koch et al. (27). 
Quantitation  of Western blots was performed as follows: ~251-protein A (New 
England  Nuclear,  Boston,  MA) was  used  as a  second  antibody  instead  of 
peroxidase-conjugated sheep anti-rabbit  IgG (Biosys, Compiegne, France). The 
blot was rinsed, air dried, and exposed to X-ray film between screens (Cronex 
double-lightning;  DuPont  Co.,  Wilmington,  DE). Autoradiographs  were 
scanned on a Helena Laboratories Quick Scan densitometer  (Desaga, Heidel- 
berg, Federal Republic of Germany), and peaks were cut out and weighed. 
Fusion Assay 
The assay for cell-cell  fusion after microinjection  of BHK-21 cells has been 
described (27). 
Biosynthetic Labeling and Use of Tunicamycin 
Cells were labeled 30 h after transfection with [35S]methionine (800 Ci/mmol; 
Amersham Corp., Arlington Heights, IL) at  I mCi/5-cm  dish. The cells were 
washed twice with  DME  minus methionine,  starved  for  15  min,  and then 
incubated  in  DME  minus methionine  plus the [35S]methionine for  1 h. To 
study glycosylation, cells were incubated  in 4 ~M tunicamyein  (Calbiochem- 
Behring Corp.,  La Jolla, CA) for 2.5  h, labeled for  1 h  (in the  presence of 
tunicamyein), and then lysed. 
Immunoprecipitation 
5-cm dishes of transfected cells were placed on ice and washed twice with ice- 
cold phosphate-buffered saline. This was replaced with 500 ,~1 of lysis buffer 
(1% Nonidet  P-40, 150 mM NaCI, 50 mM Tris, pH 7.5) supplemented with a 
range of protease inhibitors (phenylmethylsulfonyl fluoride, leupeptin, trasylol, 
pepstatin, benzamidine,  and antipain  [all from Sigma Chemical Co.], used as 
described in reference 37). After 5 min on ice, the cell lysate was removed and 
spun for 2 rain in a microfuge to remove nuclei and other insoluble material. 
For immunoprecipitation,  the volume and composition of the buffer were then 
adjusted to 1% Nonidet P-40, 1% deoxycholate, 0.1% SDS, 150 mM NaCI, 50 
mM Tris, pH 7.6, in  1 ml. 50 ul of Pansorbin  (Calbiochem-Bchring Corp.) 
washed in lysis buffer was added and the lysate rocked at room temperature 
for 30 min. After centrifugation at  100,000 g for l  h at 4"C, the supernatant 
was incubated  overnight at 4"C with  1 ul rabbit anti-E2  IgG or  l0 ~1 of an 
aMnity-purified fraction prepared from this. 50 ul of Pansorbin was added, and 
the mixture rocked at room temperature  for 30 min. The Pansorbin was then 
repeatedly washed and pelleted in a microfuge with the following buffers: lysis 
buffer plus 5 mM EDTA (twice); lysis buffer plus EDTA plus 350 mM NaC1 
(once); and  10 mM Tris, pH 7.5 (twice). The final pellet was re,suspended in 
50 ul of sample buffer (200 mM Tris, pH 8.8, 1.0 M sucrose, 0.01% bromo- 
phenol blue, 5 mM EDTA, 4%  SDS), reduced with dithiothreitol,  heated to 
95"C for 5 min, and alkylated with iodoacetamide. 
Results 
Construction of the SFV-A Mutants 
The  three  mutants  of the  membrane-binding  polypeptide 
region (Fig.  1) of p62/E2 have been constructed using oligo- 
nucleotide-directed mutagenesis (55).  Briefly, the procedure 
begins with generating an ssDNA copy of the region to be 
mutated.  An  oligonucleotide containing the desired altera- 
tions plus wild-type overlaps at each end is hybridized to the 
ssDNA template and used as a primer for DNA polymerase I 
to convert this material back to dsDNA in vitro. The in vitro- 
synthesized heteroduplex is then replicated in vivo and daugh- 
ter plasmids containing the mutation are isolated.  The mu- 
Wild Type 
AI 
A2 
A3 
NH2  Lumenot  Tronsmembrone  Cylvplnsmic  .....  COOH 
....  ~]PH  GWPH O,I VCtYYYGLYPAAT V  ~:  ~ S~C LTPYALT  ..... 
....  ® 
....  [] 
....  G-M  -- 
AI  A 2  A3 
G  G  A  G  T 
Mutngenic o[igonucleotides used  GGCC GCAGT AGTGC  GATETTEG  GTEGTGC  GGE[ GCAGTA GTGC 
Wild-Type  template strand  CCGG CGTEA TCACG  CTAGAAGC CAGEACG  [EGG [GTCAT [ACG 
G  T  G  G  T 
Figure 1. Predicted primary structures of the SFV-A mutants. This schematic diagram, using the single-letter code of the amino acid sequence 
around the membrane-spanning region, includes the following features: basic amino acids are boxed, acidic are encircled. The shaded region 
of the wild type indicates the probable membrane-spanning region. The amino acids indicated  in the mutants are those changed from wild 
type. The mutagenic oligonucleotides used to make the changes are shown, along with the corresponding region of  template. The oligonucleotides 
are shown 5' to 3' left to right. The mismatches are indicated by raising (in the mutagen) and lowering (in the template) the relevant bases. 
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Figure  2,  Flow  diagrams 
(not to  scale) of the  con- 
struction of  the SFV-A mu- 
tants.  A  (left  page)  shows 
the  steps  involved  in  the 
construction  of  SFV-A1 
and SFV-A2. B (right page) 
shows the steps involved in 
the  construction  of SFV- 
A3. Two concentric  circles 
indicate  dsDNA,  a  single 
circle indicates  ssDNA.  In 
pSFd  (A), the  SFV  tran- 
script  is  indicated  in  the 
outer semicircle with boxed 
coding  region.  Functional 
regions  of  the  plasmids 
pSFd  and  pS-S-SFV in  A 
are indicated:  solid (black) 
color,  SFV  eDNA;  hatch- 
ing, SV40 early promoter; 
cross-hatching  polyadeny- 
lation signals for SV40; stip- 
pling, Fi  origin of replica- 
tion;  unshaded,  pBR322 
ampicillin  resistance  and 
origin  of  replication.  Ar- 
rowheads  within  plasmids 
indicate the action of DNA 
polymerase. 
i 
(A)n 
E2 
\ 
Ampr 
sid  E1  ...A.. 
otigo 
~ inase. 
~neatl~g 
+sot~ition ~f singte-  • 
stranded pSFd 
f~,,~rogmSst  II digest,  olate  smart 
ent 
Sst lldigest,  tigotion  • 
phosphatose, 
isolate  large 
fragment 
]/~frunsfocm, 
replicate, 
tagenic oligonucleotides and complementary template regions 
used  to  create  the  SFV-A  mutants  are  shown  (with  mis- 
matches) in Fig.  I. The oligonucleotides were designed both 
to make the desired amino acid changes and to introduce new 
restriction sites into the DNA to facilitate screening for mu- 
tated  plasmids.  Al  and  A3 introduce HpaII sites  (CCGG), 
whereas A2 introduces a TaqI site (TCGA). 
The strategies used for mutagenesis (Fig, 2, a  and b) were 
designed  to  minimize  undesired  mutations  caused  by  the 
oligonueleotide hybridizing to secondary sites on the template 
ssDNA, resulting in false positives during screening. Because 
the SFV eDNA is 3,983 base pairs long (14), many such sites 
existed,  and  were  used  by  the  mutagenic  oligonucleotides 
(Cutler, D., unpublished observations). Thus, for SFV-A 1 and 
SFV-A2 (Fig. 2a), the region of mutagenized DNA that was 
screened was limited to a  149-base pair SstlI-SstlI fragment 
transferred  to a  wild-type vector.  The  ssDNA template  for 
SFV-AI  and  SFV-A2 was produced  using the  approach of 
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Dente et al. (10). The portion ofa ssDNA phage (FI) required 
in  cis for generation of SSDNA was cloned into the SV40- 
based expression vector pS-S-SFV (see Fig. 3 a) to give pSFd 
(Fig.  2 a). Superinfection of bacteria harboring this plasmid 
with a helper phage allows the isolation of sspSFd. The use of 
pSFd allowed mutants to be rapidly tested by expression. The 
efficiency of mutagenesis with this system was -0.5-1%. 
For the creation of SFV-A3  (Fig. 2 b), the initial target for 
hybridization of  the oligonucleotide was limited to a 750-base 
pair Pvu II-Sca I segment by a gapped heteroduplex approach 
893  Cutler and Garoff Transport and Fusion of  SFV E2 Mutants Figure 3.  DNA  sequence of the 
SFV-A mutations.  The  sequence 
of the three mutant  149-base pair 
Sstll-gs~ll fragmenls used in these 
s~udies are shown. L~ne headings 
indicate dideoxy~ucteoti~e~ used, 
The  Sstll recognition  sequences 
are indicated as are the positions 
of incoqDorated mutagenic oligo- 
nucleotides. ~tarred bases in  the 
oligonucleotides indicate changes 
from the wild-type sequence. 
(28). The single-stranded template/'or SFV-A3 was produced 
by subcloning the 750-base pair fragment of the SFV eDNA 
into a plasmid based on an ssDNA phage, M13-mp8 (39), to 
produce M13-mp8-SFV.  The use of the mp8/mpl8 gapped 
duplex strategy allows genetic selection for the mutagenized 
daughter plasmids; by using the  nonsuppressor host ES781 
(6), lhe mp8-derived wild-type daughter plasmids are selected 
against since rap8 (unI~ke mpI 8) carries two amber mutations. 
ES781  has  the  additional  advantage  that  it  also  lacks  the 
Mutt  mismatch  repair system and  so  will  not  convert the 
heteroduplex  plasmids  to  homoduplexes,  a  process  which 
normally favors the in vivo-methylated wild-type strand and 
therefore reduces the yield (29). The efficiency of mutagenesis 
in M13mp8-SFV was about  10-fold greater than with pSFd, 
5-10%.  All  three  mutants  were  isolated  by  hybridization 
screening (7) followed by restriction analysis and confirmed 
by sequencing  using the  dideoxy method  between  the  two 
flanking SstII sites (Fig. 3). The Sstll-SstII fragment was then 
subcloned into  the  expression  vectors used  in  these studies 
ensuring ~hat only the desired mutations were present ir~ the 
protein~  being analyzed. 
Expression of  p62/E2 with and without E1 
The  SstlI-SstlI  fragments  encoding  the  A-mutants  were 
cloned into two different kinds of SFV expression plasmids; 
pS-S-SFV and pL1-SFV. The first (Fig.  4a) is based on the 
SV40  early  region  and  has been  described  (27).  The latter 
(Fig. 4b) is the SV40 late region expression vector of Gruss et 
al. (18) with the SFV-cDNA inserted (Melancon, P.,  unpub- 
lished data). The pS-S:SFV series of plasmids encoding wild- 
type and mutant cDNAs were used for microinjection exper- 
iments.  The pLI-SFV series  were  transfected  into  COS-7 cells 
where the  endogenously expressed  T-antigen  promotes repli- 
cation  and transcription  from the late  region  of  SV40 DNA. 
This amplification facilitated experiments where the proteins 
produced were analyzed by electrophoresis. Since El, which 
is co-expressed with p62 from gFV expression plasmids, may 
he?l~ to stabilize the latter }n the membrane (m the p62-E1 
spike complex) and theretbre mask alterations in ~t5 pheno- 
type, p62 has been expressed and analyzed both in the pres- 
ence and the absence of E1 (see Fig. 5). To express p62 in the 
absence of El, we have used the plasmid pL1-SFV-d9 where 
the SFV eDNA is truncated in the middle of the 6K-peptide 
region  (up  to  the  codon  for Ala  24).  This  60-amino  acid 
residue peptide is found between p62 and E1  and is cleaved 
away eo-translationally. The p62 protein produced from pL1- 
SFV-d9  wilt,  most likely,  undergo  normal  E2/6K  cleavage 
and give rise to a p62 without the aberranl amino acids at its 
carboxyl lerminus commonly introduced in lruncations (e.g., 
9.  rS).  The  ~runcation  SFV-d9  ~F~g. 5)  }s  or2e of a  series 
described elsewhere (15) and has been subcloned into pAll- 
SVL2  to  produce  pL1-SFV-d9  (Fig.  4c  and  Materials  and 
Methods). 
Size and Glycosylation of the SFV-A Mutants 
The first analysis of the SFV-A mutants was designed to show 
that the wild-type and  mutant p62 proteins expressed from 
both pL1-SFV and pLI-SFV-d9 are the expected sizes, with 
and  without  oligosaccharides.  Accordingly,  two  sets  of all 
eight  plasmids (wild-type and  mutants,  pLI-SFV and  pkl- 
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Figure 4. Expression vectors used in these experiments. Drawn to the same scale, these diagrams show both the functional units in the DNA 
(inner circles) and the predicted RNA transcripts (outer circles) with the regions coding for SFV proteins boxed. In the DNA, a solid thick line 
indicates SFV coding region. A  hatched  region includes the SV40 early promoter (pS-S-SFV)  or the early and late promoters, origin of 
replication plus the beginning of the T-antigen gene (pLI-SFV and pLI-SFV-d9). The region with circles  includes the rest of the T-antigen 
coding region and SV40 polyadenylation signals. Cross-hatching (pS-S-SFV) indicates polyadenylation signal for SV40. 
SFV  SFV- d9 
p62 
Lumen 
Cytoptosm  /  f 
N  N 
Ctlpsld  ~  C~ 
Figure 5.  The SFV spike,  and the SFV-d9 deletion. The proteins 
(capsid-Ea-E2-6K-El) encoded by the  full length SFV-cDNA and 
SFV-d9 (capsid-E3-E2)  are shown. The region deleted in d9 is shown 
as an  interrupted  line. The  sites of proteolytic processing of the 
polyprotein precursor are shown by double perpendicular lines. The 
disposition of the 6K peptide in the membrane is hypothetical. 
SFV-d9)  were  transfected  into  COS-7  cells  using  DEAE- 
dextran (Materials and Methods). 30 h after transfection, one 
set of dishes was treated with tunicamycin and both were then 
pulse labeled with [35S]methionine  followed by solubilization, 
immunoprecipitation, gel electrophoresis, and fluorography 
(Fig.  6).  Lanes 2-9 show that in cells transfected with pL1- 
SFV (and therefore co-expressing E2 and El), the AI and A3 
forms of p62s  migrate with  the wild-type p62  both  in  the 
presence (a) or  the  absence (b)  of NH2-1inked  sugars.  The 
concentration of tunicamycin sufficient to completely prevent 
N-glycosylation also  inhibits  protein  synthesis considerably 
(compare even and odd tracks). The A2 form of p62, on the 
other hand, consistently migrates a little slower on SDS pol- 
yacrylamide gels,  a  pattern  maintained  in  the  presence of 
tunicamycin. In cells transfected with pLI-SFV-d9 and there- 
fore lacking E 1 (tracks 10-17), p62 migrates as a doublet. The 
major,  faster-migrating form of p62  co-migrates with  p62 
produced in the presence of E 1.  This is consistent with the 
expected E2/6K cleavage. The A-mutants are glycosylated as 
wild-type, A2 again migrating slower. The slower migrating 
p62  form  seen  in  the  absence  of E1  is  probably not  the 
uncleaved p62-6K protein  since the predicted difference in 
molecular weight resulting from this cleavage in  SFV-d9  is 
too small to account for the difference in mobility, p62 often 
runs as multiple bands on SDS gels (see, for example, refer- 
ence  15), possibly due  to  different  conformations  of this 
cysteine-rich protein. It may be that the absence of E 1 exag- 
gerates this tendency--more marked in the case of A2 (see 
lane 4 where a doublet occurs even in the presence of E 1). 
An alternative possibility, that the upper band is an interme- 
diate in posttranslational modification has been tested. A 4-h 
chase does not alter this banding pattern (Cutler, D., unpub- 
lished observations). However, the doublet is not always pres- 
ent in samples analyzed by Western blot 40 h after transfection 
(see, for example, Fig. 3 in the following paper), and therefore 
may result from some incomplete posttranslational modifi- 
cation. The aberrant mobility of  A2-p62 may be due to altered 
SDS binding since a  charge has been placed into the most 
hydrophobic portion of the molecule. Interestingly, the level 
of expression of p62 is approximately three- to fivefold better 
in the absence of E 1. Shortening the SFV cDNA consistently 
produces  higher  levels  of expression  after  DEAE--dextran 
transfection (Melancon,  P., and D. Cutler, unpublished ob- 
servations). Lane 1 shows the nonspecific bands immunopre- 
cipitated in this experiment. 
Cell Surface Transport of the SFV-A Mutants 
One of the simplest ways to test whether or not the A-mutants 
are still membrane associated is to look for cell surface expres- 
sion. If the proteins are on the cell surface then they are still 
membrane  associated.  Moreover,  we  can  use  cell  surface 
transport as a  screen against possible pleiotropic effects of 
mutagenesis since the  cellular machinery will  often  fail to 
transport  proteins with  even relatively small alterations  in 
primary structure (3). Unaltered cell surface transport would 
be evidence of a functionally unaltered protein. Accordingly, 
895  Cutler and Garoff Transport and Fusion of  SFV E2 Mutants Figure 6.  Size and glycosylation of the SFV-A mutants.  5-cm dishes of COS cells were transfected,  labeled with  or without  tunicamycin 
treatment,  and  lysed. Lysates were  immunoprecipitated  with  an  anti-E2  IgG  fraction,  electrophoresed  on  a  10%  gel, and  the  gel was 
fluorographed.  The samples transfected  (HIT, A3, A2, AI refer to the wild-type and mutant spikes expressed from pLl-SFV; the d9, d9Al, 
d9A2, d9A3 refer to the wild-type and mutant p62's expressed from pLI-SFV-d9) and the presence or absence of tunicamycin are indicated. C 
indicates untransfected cells. The migration of marker proteins (in kD) is indicated, a and b refer to p62 produced in the absence or presence 
of tunicamycin,  respectively. The product of half of one dish (~ 1 x  106 cells) of cells was loaded onto each track. Lanes 2-9 were from a 4-d 
exposure to an insensitive X-ray film, and lanes l, and 10-17 from an overnight exposure to a sensitive film, all from one gel. 
the pS-S-SFV versions of  the wild-type and mutant SFVs were 
microinjected into  BHK-21  cells and distribution  was ana- 
lyzed by surface and internal  indirect immunofluorescence. 
Fig. 7, a  and b, shows that all three  mutants are capable of 
reaching the cell surface. The internal staining (Fig. 7, c-e) of 
cells microinjected with both wild-type and mutant cDNAs 
shows  a  reticular  pattern  with  a  perinuclear  concentration 
and  clearly  visible  cellular  margins,  typical  for  a  normal 
plasma membrane protein. This fluorescent analysis has been 
repeated in COS-7 cells,  following expression from the pL1- 
SFV series after DEAE-dextran transfection. The results ob- 
tained are  similar to those seen with BHK-21  cells (Cutler, 
D., unpublished observations). 
Can the A-mutant p62 proteins reach the cell surface in the 
absence of El? Transfection of  COS-7 cells with the four pL1- 
SFV-d9  plasmids  followed by surface  and  internal  indirect 
immunofluorescence (Fig.  8) shows that E1  is not required 
for surface appearance of the wild-type and the A-mutants of 
p62. 
A fluorescent analysis of surface transport has limitations. 
It  will  not  reveal  small  differences  between  wild-type  and 
mutant p62s and cannot be used to rule out the possibility 
that only a  subpopulation of the protein is reaching the cell 
surface.  To pursue  these  latter  points,  the  posttranslational 
processing of p62 into E3 +  E2 has been exploited to achieve 
an indirect measure of cell surface appearance. This cleavage 
is taking place either on the cell surface and/or just before the 
p62 proteins arrive to the cell surface; E2 is not found within 
the cell but only on its surface and in budded virions during 
infection (48). Transfection experiments reported earlier (l 5, 
27) and in the accompanying paper (see in particular Fig. 3 
of that report) have shown that efficient cleavage can only be 
obtained when the p62  protein  is co-expressed with the E1 
glycoprotein. Presumably, the El-p62 interaction in the SFV 
spike glycoprotein supports a conformation recognized by the 
endoprotease.  Furthermore,  it is evident from Fig, 6  in this 
paper that long incubation times are needed to process the 
p62 protein in pL1-SFV DNA-transfected COS cells.  After a 
l-h pulse (without chase) of  transfected cells, there is still very 
little  E2  protein  appearing both  for wild-type and  mutants 
(see faint band co-migrating with a nonspecific one in the 50- 
kD region in lanes 2-9 of Fig. 6). For these reasons, the ratio 
of total  p62  to  E2  has  been  measured  in  cells  40  h  after 
transfection, in the presence of El, using the pLI-SFV wild- 
type and  mutant DNAs.  After solubilization,  samples  were 
electrophoresed and transferred to nitrocellulose and stained 
with anti-E2 antibody followed by 125I-protein A. Autoradi- 
ographs were scanned for quantitation.  The results of three 
experiments (Table I) show E2/p62 ratios of about 2 both for 
The Journal of Cell Biology, Volume 102, 1986  896 Figure  7.  Surface  and  internal 
fluorescence ofBHK-21 cells mi- 
croinjected to produce wild-type 
and mutant SFV spikes. Nuclei 
of BHK-21  cells were  microin- 
jected  with  the  pS-S-SFV con- 
structs,  fixed  6  h  later,  and 
stained with anti-E2 antibody or 
first  permeabilized  and  then 
stained. Rows a and b show im- 
munofluorescence  and  corre- 
sponding  phase-contrast  images 
of nonpermeabilized  cells. Rows 
d  and  e  show  immunofluores- 
cence and corresponding  phase- 
contrast images of permeabilized 
cells. Row c shows cells treated 
as in d but at a 2.5-fold greater 
magnification. Bars, 20 um. 
the wild-type protein  and all  of the  mutants.  We conclude 
that all p62 mutants are transported to the cell surface with 
an efficiency similar to that of wild-type p62 protein. 
Fusogenic Activity of the SFV-A Mutants 
A  function of the SFV spike complex that is directly related 
to its membrane binding is its activity as a  fusogen. For the 
spike to promote fusion it must be anchored in a lipid bilayer 
(36). It might be thal fusion activity would be a very sensitive 
assay for functionally intact membrane binding. BHK-21 cells 
were microinjected with the four pSV-S-SFV plasmids con- 
taining the wild-type and A-mutant SFVs, left for 6  h, then 
briefly  treated  with  low  pH.  After  fixation,  the  cells  were 
stained with anti-E2 antibody and photographed. Fig. 9 shows 
that all three mutant spikes, like the wild-type spike, exhibit 
fusogenic activity. In all cases, the microinjected cells express- 
897  Cutler and Garoff Transport and Fusion of  SFV E2 Mutants Figure 8.  Surface  and  internal  fluorescence of COS-7  cells transfected  to  produce  wild-type  and  mutant  p62  proteins.  COS-7  cells were 
transfected with the pL1-SFV-d9 constructs, left 40 h, fixed, and then stained with an anti-E2 antibody (right-hand columns) or permeabilized 
and then stained (left-hand columns). Fluorescent and corresponding Nomarski micrographs are shown. Bar, 20 #m. 
ing wild-type or mutant spikes become a part of large poly- 
karyons. 
Table I. Ratio of E2 to p62 in Cells Transfected with pLI- 
SFV Encoding Wild-type and Mutant E2/p62 Proteins 
Sample  Wild type  A 1  A2  A3 
Discussion  E2/p62*  2.1  _+ 0.14  1.8 _+ 0.28  1.9 _+ 0.74  1.7 +  0.2 
In this paper the generation  of three mutants of the  mem- 
brane-binding polypeptide region of  SFV-p62/E2 is described. 
After expression, the mutated DNAs express proteins of the 
predicted size. These are glycosylated and transported to the 
cell surface as is the wild-type p62/E2, both in the presence 
and  absence  of El.  Moreover,  all  three  spikes  made with 
mutated p62/E2 display fusogenic activity. 
The demonstration of normal cell surface appearance and 
fusogenic activity for the SFV-A mutants rules out the possi- 
bility that the mutations have completely destroyed the func- 
tioning of the membrane-binding region of the p62/E2 poly- 
peptide.  Moreover, cell surface appearance is an important 
feature of our mutants since we wanted to make only those 
minimal alterations to p62/E2  structure that are consistent 
with alterations to its membrane-binding polypeptide region. 
The  field of mutagenesis/expression shows many examples 
where  engineering  at  the  DNA  level  has  led  to  impaired 
intracellular transport (e.g.,  references  12,  19,  38,  and  46). 
These results are often very difficult to interpret and so we 
have attempted to produce proteins that are as little perturbed 
as possible; efficient cell surface transport argues that we have 
achieved this. 
Our  results  with  A2  are  in  contrast  with  those  recently 
published by Adams and Rose (1). They show that the sub- 
Cells transfected with indicated DNAs were  solubilized  after 40  h.  Samples 
were  Western blotted  and  stained with anti-E2  antibody followed  by  J:Sl- 
protein A. Autoradiographs were  scanned, peaks cut out, and weighed.  Data 
presented is the mean of three experiments _+ SEM. 
* The weight of the E2 peak/the weight of the I)62 peak. 
stitution of an Arg for an Ile in the middle of the hydrophobic 
stretch of VSV-G seriously inhibits its surface transport. There 
are at least two possible reasons for this difference in result. 
If  the interaction between lipid bilayer and hydrophobic span- 
ning stretch is important for intracellular transport then dis- 
rupting this interaction could inhibit that transport. Arg could 
well be more disruptive than Glu (31).  Moreover, while the 
membrane-spanning stretch of VSV-G is defined by a charge 
at both ends, that of p62/E2 does not have a charge-defined 
NH2-terminal border (see Fig.  1). Thus p62/E2 may be able 
to  slide  upstream  in  the  mechanism, thereby avoiding the 
problem of burying a charge in the bilayer. A second possi- 
bility is that oligomerization .of VSV-G is important for its 
cell surface transport and that the  mutation affects this.  In 
the  case  of SFV,  the  spike  of which  is  a  hetero-oligomer 
(unlike the glycoprotein of VSV),  it could be either that Glu 
does not affect oligomerization or that the transport of p62 is 
not very sensitive to its oligomeric state. This may well be so 
The Journal of Cell Biology, Volume 102, 1986  898 Figure 9.  Fusion activity of wild-type and SFV-A mutant spikes.  BHK-21 cells were microinjected with the pS-S-SFV constructs, left for 6 h, 
then briefly washed with medium at pH 5.5 and left for 1 h. They were then fixed and stained with anti-E2 antibody.  Immunofluorescence 
and the corresponding phase-contrast images are shown. Bar, 20 um. 
since p62 can reach the cell surface in the absence of E 1. 
We  have  argued  that  since  membrane  binding  of spike 
proteins is essential for fusion (36) and all three mutants of 
p62/E2 cause cell-cell fusion, all three SFV-A-mutants have 
unaltered membrane binding. However, the fusion activity of 
the SFV spike has only been found when the whole complex 
is expressed; p62  expressed alone cannot cause fusion (27). 
This result implies that SFV-E1  may have a primary role in 
fusion. However, when expressed alone, El, although glyco- 
sylated and  therefore translocated,  does  not  reach  the  cell 
surface (22,  and Melancon, P., unpublished data) and there- 
fore we have no positive confirmation of a primary fusogenic 
role for E1 in SFV.  Thus, it may be that both E1 and E2 are 
required in concert to mediate fusion (52). That our mutations 
do not appear to affect fusion may therefore reflect either that 
p62/E2 is not involved in fusion or that they do not impair 
functional membrane binding ofp62/E2. 
Both assays of membrane association presented here are 
functional and therefore indirect. It could be that the position 
and/or stability of the mutant proteins in the membrane is 
altered in these mutants despite their unimpaired functioning. 
In the following paper, we directly address these questions. 
The general implication of the results presented here is that 
it is unlikely that a specific structure present in the membrane- 
899  Cutler and Garoff Transport and Fusion of  SFV E2 Mutants binding  polypeptide  region is being recognized by some  ma- 
chinery  involved  in  translocation  leading  to  the  halting  of 
transfer. Our data tend to support a  model in which a  general 
hydrophobicity  causes a  transmembrane  protein  to  assume 
its three-domain  structure,  and  that  an  intact charge duster 
and uninterrupted  hydrophobic  stretch are not important  for 
this function. 
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